321 related articles for article (PubMed ID: 26075833)
21. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
[TBL] [Abstract][Full Text] [Related]
22. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Edwards JE; Eliot L; Parkinson A; Karan S; MacConell L
Adv Ther; 2017 Sep; 34(9):2120-2138. PubMed ID: 28808886
[TBL] [Abstract][Full Text] [Related]
23. Short-term fasting alters cytochrome P450-mediated drug metabolism in humans.
Lammers LA; Achterbergh R; de Vries EM; van Nierop FS; Klümpen HJ; Soeters MR; Boelen A; Romijn JA; Mathôt RA
Drug Metab Dispos; 2015 Jun; 43(6):819-28. PubMed ID: 25795462
[TBL] [Abstract][Full Text] [Related]
24. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Ermer J; Corcoran M; Martin P
Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
[TBL] [Abstract][Full Text] [Related]
25. Utility of non-human primates in drug development: Comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes.
Uno Y; Uehara S; Yamazaki H
Biochem Pharmacol; 2016 Dec; 121():1-7. PubMed ID: 27318253
[TBL] [Abstract][Full Text] [Related]
26. Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
de Vries EM; Lammers LA; Achterbergh R; Klümpen HJ; Mathot RA; Boelen A; Romijn JA
PLoS One; 2016; 11(7):e0159552. PubMed ID: 27434302
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
Johnson BM; Song IH; Adkison KK; Borland J; Fang L; Lou Y; Berrey MM; Nafziger AN; Piscitelli SC; Bertino JS
J Clin Pharmacol; 2006 May; 46(5):577-87. PubMed ID: 16638741
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.
Tandra S; Chalasani N; Jones DR; Mattar S; Hall SD; Vuppalanchi R
Ann Surg; 2013 Aug; 258(2):262-9. PubMed ID: 23222033
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
30. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
31. Prediction of the Area under the Curve Using Limited-Point Blood Sampling in a Cocktail Study to Assess Multiple CYP Activities.
Miura M; Tanaka S; Uchida S; Kamiya C; Katayama N; Hakamata A; Odagiri K; Inui N; Kawakami J; Watanabe H; Namiki N
Biol Pharm Bull; 2021; 44(6):762-770. PubMed ID: 34078808
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous determination of tolbutamide, omeprazole, midazolam and dextromethorphan in human plasma by LC-MS/MS--a high throughput approach to evaluate drug-drug interactions.
Zhang W; Han F; Guo P; Zhao H; Lin ZJ; Huang MQ; Bertelsen K; Weng N
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(15-16):1169-77. PubMed ID: 20378422
[TBL] [Abstract][Full Text] [Related]
33. Quantitative Prediction of Human Hepatic Clearance for P450 and Non-P450 Substrates from In Vivo Monkey Pharmacokinetics Study and In Vitro Metabolic Stability Tests Using Hepatocytes.
Nishimuta H; Watanabe T; Bando K
AAPS J; 2019 Jan; 21(2):20. PubMed ID: 30673906
[TBL] [Abstract][Full Text] [Related]
34. Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
Lammers LA; Achterbergh R; Romijn JA; Mathôt RAA
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):251-257. PubMed ID: 28929443
[TBL] [Abstract][Full Text] [Related]
35. Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound.
Mao J; Fan P; Wong S; Wang J; Ismaili MHA; Dean B; Hop CECA; Wright M; Chen Y
Pharm Res; 2017 Nov; 34(11):2403-2414. PubMed ID: 28815392
[TBL] [Abstract][Full Text] [Related]
36. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6.
Jiang X; Zhuang Y; Xu Z; Wang W; Zhou H
AAPS J; 2016 May; 18(3):767-76. PubMed ID: 26961818
[TBL] [Abstract][Full Text] [Related]
37. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Flaherty KT; Lathia C; Frye RF; Schuchter L; Redlinger M; Rosen M; O'Dwyer PJ
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1111-8. PubMed ID: 21350850
[TBL] [Abstract][Full Text] [Related]
38. Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys.
Zhang H; Zhang D; Li W; Yao M; D'Arienzo C; Li YX; Ewing WR; Gu Z; Zhu Y; Murugesan N; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 May; 35(5):795-805. PubMed ID: 17303626
[TBL] [Abstract][Full Text] [Related]
39. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN
Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145
[TBL] [Abstract][Full Text] [Related]
40. A comparison of pharmacokinetics between humans and monkeys.
Akabane T; Tabata K; Kadono K; Sakuda S; Terashita S; Teramura T
Drug Metab Dispos; 2010 Feb; 38(2):308-16. PubMed ID: 19910513
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
